Our study also demonstrated that knockdown of SMYD3 increased cell sensitivity to doxorubicin and vincristine in DLBCL cell lines and high expression of SMYD3 in DLBCL FFPE tissues was associated with poor response to the chemotherapy. The gene discussed is SMYD3; the disease is diffuse large B-cell lymphoma.